nach oben

Die Ophthalmologie

Erschienen in:

16.04.2021 | CME

Chorioretinopathia centralis serosa

verfasst von: Laurenz Pauleikhoff, Hansjürgen Agostini, Prof. Dr. Clemens Lange

Erschienen in: Die Ophthalmologie | Ausgabe 9/2021

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Chorioretinopathia centralis serosa (CCS) ist nach der altersbedingten Makuladegeneration, der diabetischen Retinopathie und dem retinalen Venenverschluss die vierthäufigste Erkrankung der Makula und eine Ursache für irreversible Sehminderung. Diese Arbeit gibt einen Überblick über die Epidemiologie, Risikofaktoren, Pathophysiologie, klinische Präsentation, multimodale Bildgebung und diskutiert die aktuellen Therapiemöglichkeiten der CCS.

Von Graefe A (1866) Über zentrale rezidivierende Retinitis. Graefes Arch Clin Exp Ophthalmol 12:221CrossRef

Gass JD (1967) Pathogenesis of disciform detachment of the neuroepithelium. Am J Ophthalmol 63(Suppl):1–139

Wang M, Munch IC, Hasler PW et al (2008) Central serous chorioretinopathy. Acta Ophthalmol 86:126–145. https://doi.org/10.1111/j.1600-0420.2007.00889.xCrossRefPubMed

Kitzmann AS, Pulido JS, Diehl NN et al (2008) The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980–2002. Ophthalmology 115:169–173. https://doi.org/10.1016/j.ophtha.2007.02.032CrossRefPubMed

Spaide RF, Campeas L, Haas A et al (1996) Central serous chorioretinopathy in younger and older adults. Ophthalmology 103:2070–2079 (discussion 2079–2080)CrossRef

Quillen DA, Gass JDM, Brod RD et al (1996) Central serous chorioretinopathy in women. Ophthalmology 103:72–79. https://doi.org/10.1016/S0161-6420(96)30730-6CrossRefPubMed

Bousquet E, Beydoun T, Zhao M et al (2013) Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study. Retina 33:2096–2102. https://doi.org/10.1097/IAE.0b013e318297a07aCrossRefPubMed

Daruich A, Matet A, Dirani A et al (2015) Central serous chorioretinopathy: recent findings and new physiopathology hypothesis. Prog Retin Eye Res 48:82–118. https://doi.org/10.1016/j.preteyeres.2015.05.003CrossRefPubMed

Carvalho-Recchia CA, Yannuzzi LA, Negrão S et al (2002) Corticosteroids and central serous chorioretinopathy. Ophthalmology 109:1834–1837. https://doi.org/10.1016/s0161-6420(02)01117-xCrossRefPubMed

10.

Haimovici R, Rumelt S, Melby J (2003) Endocrine abnormalities in patients with central serous chorioretinopathy. Ophthalmology 110:698–703. https://doi.org/10.1016/S0161-6420(02)01975-9CrossRefPubMed

11.

Wakakura M, Song E, Ishikawa S (1997) Corticosteroid-induced central serous chorioretinopathy. Jpn J Ophthalmol 41:180–185. https://doi.org/10.1016/s0021-5155(97)00027-0CrossRefPubMed

12.

Zhao M, Célérier I, Bousquet E et al (2012) Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. J Clin Invest 122:2672–2679. https://doi.org/10.1172/JCI61427CrossRefPubMedPubMedCentral

13.

Zhao M, Valamanesh F, Celerier I et al (2010) The neuroretina is a novel mineralocorticoid target: aldosterone up-regulates ion and water channels in Müller glial cells. FASEB J 24:3405–3415. https://doi.org/10.1096/fj.09-154344CrossRefPubMed

14.

Giusti C (2004) Association of Helicobacter pylori with central serous chorioretinopathy: hypotheses regarding pathogenesis. Med Hypotheses 63:524–527. https://doi.org/10.1016/j.mehy.2004.02.020CrossRefPubMed

15.

Siedlecki J, Schworm B, Priglinger SG (2019) The Pachychoroid disease spectrum-and the need for a uniform classification system. Ophthalmol Retina 3:1013–1015. https://doi.org/10.1016/j.oret.2019.08.002CrossRefPubMed

16.

Liu B, Deng T, Zhang J (2016) Risk factors for central serous chorioretinopathy: a systematic review and meta-analysis. Retina 36:9–19. https://doi.org/10.1097/IAE.0000000000000837CrossRefPubMed

17.

Conrad R, Weber NF, Lehnert M et al (2007) Alexithymia and emotional distress in patients with central serous chorioretinopathy. Psychosomatics 48:489–495. https://doi.org/10.1176/appi.psy.48.6.489CrossRefPubMed

18.

Conrad R, Geiser F, Kleiman A et al (2014) Temperament and character personality profile and illness-related stress in central serous chorioretinopathy. ScientificWorldJournal 2014:631687. https://doi.org/10.1155/2014/631687CrossRefPubMedPubMedCentral

19.

Yannuzzi LA (1987) Type‑A behavior and central serous chorioretinopathy. Retina 7:111–131. https://doi.org/10.1097/00006982-198700720-00009CrossRefPubMed

20.

van Dijk EHC, Schellevis RL, van Bergen MGJM et al (2017) Association of a Haplotype in the NR3C2 gene, encoding the mineralocorticoid receptor, with chronic central serous chorioretinopathy. JAMA Ophthalmol 135:446–451. https://doi.org/10.1001/jamaophthalmol.2017.0245CrossRefPubMedPubMedCentral

21.

de Jong EK, Breukink MB, Schellevis RL et al (2015) Chronic central serous chorioretinopathy is associated with genetic variants implicated in age-related macular degeneration. Ophthalmology 122:562–570. https://doi.org/10.1016/j.ophtha.2014.09.026CrossRefPubMed

22.

Miki A, Kondo N, Yanagisawa S et al (2014) Common variants in the complement factor H gene confer genetic susceptibility to central serous chorioretinopathy. Ophthalmology 121:1067–1072. https://doi.org/10.1016/j.ophtha.2013.11.020CrossRefPubMed

23.

Haimovici R, Koh S, Gagnon DR et al (2004) Risk factors for central serous chorioretinopathy: a case-control study. Ophthalmology 111:244–249. https://doi.org/10.1016/j.ophtha.2003.09.024CrossRefPubMed

24.

Weber ML, Liang MC, Flaherty KT, Heier JS (2016) Subretinal fluid associated with MEK inhibitor use in the treatment of systemic cancer. JAMA Ophthalmol 134:855–862. https://doi.org/10.1001/jamaophthalmol.2016.0090CrossRefPubMed

25.

Aliferis K, Petropoulos IK, Farpour B et al (2012) Should central serous chorioretinopathy be added to the list of ocular side effects of phosphodiesterase 5 inhibitors? Ophthalmologica 227:85–89. https://doi.org/10.1159/000333824CrossRefPubMed

26.

Michael JC, Pak J, Pulido J, de Venecia G (2003) Central serous chorioretinopathy associated with administration of sympathomimetic agents. Am J Ophthalmol 136:182–185. https://doi.org/10.1016/s0002-9394(03)00076-xCrossRefPubMed

27.

Pierce KK, Lane RG (2009) Central serous chorioretinopathy associated with the use of ephedra. Retin Cases Brief Rep 3:376–378. https://doi.org/10.1097/ICB.0b013e31818ad3ceCrossRefPubMed

28.

Gilbert CM, Owens SL, Smith PD, Fine SL (1984) Long-term follow-up of central serous chorioretinopathy. Br J Ophthalmol 68:815–820CrossRef

29.

Levine R, Brucker AJ, Robinson F (1989) Long-term follow-up of idiopathic central serous chorioretinopathy by fluorescein angiography. Ophthalmology 96:854–859. https://doi.org/10.1016/s0161-6420(89)32810-7CrossRefPubMed

30.

Loo RH, Scott IU, Flynn HW et al (2002) Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy. Retina 22:19–24. https://doi.org/10.1097/00006982-200202000-00004CrossRefPubMed

31.

Maruko I, Iida T, Ojima A, Sekiryu T (2011) Subretinal dot-like precipitates and yellow material in central serous Chorioretinopathy. Retina 31:759–765. https://doi.org/10.1097/IAE.0b013e3181fbce8eCrossRefPubMed

32.

Yang L, Jonas JB, Wei W (2013) Optical coherence tomography–assisted enhanced depth imaging of central serous Chorioretinopathy. Invest Ophthalmol Vis Sci 54:4659. https://doi.org/10.1167/iovs.12-10991CrossRefPubMed

33.

Dansingani KK, Balaratnasingam C, Naysan J, Freund KB (2016) En face imaging of pachychoroid spectrum disorders with swept-source optical coherence tomography. Retina 36:499–516. https://doi.org/10.1097/IAE.0000000000000742CrossRefPubMed

34.

Lehmann M, Bousquet E, Beydoun T, Behar-Cohen F (2015) Pachychoroid: an inherited condition? Retina 35:10–16. https://doi.org/10.1097/IAE.0000000000000287CrossRefPubMed

35.

Kim JH, Kang SW, Kim JR, Kim SJ (2013) Variability of subfoveal choroidal thickness measurements in patients with age-related macular degeneration and central serous chorioretinopathy. Eye 27:809–815. https://doi.org/10.1038/eye.2013.78CrossRefPubMedPubMedCentral

36.

Usui S, Ikuno Y, Akiba M et al (2012) Circadian changes in subfoveal choroidal thickness and the relationship with circulatory factors in healthy subjects. Investig Ophthalmol Vis Sci 53:2300–2307. https://doi.org/10.1167/iovs.11-8383CrossRef

37.

Ikuno Y, Kawaguchi K, Nouchi T, Yasuno Y (2010) Choroidal thickness in healthy Japanese subjects. Invest Ophthalmol Vis Sci 51:2173–2176. https://doi.org/10.1167/iovs.09-4383CrossRefPubMed

38.

Sakurada Y, Leong BCS, Parikh R et al (2018) Association between choroidal caverns and choroidal vascular hyperpermeability in eyes with pachychoroid diseases. Retina 38:1977–1983. https://doi.org/10.1097/IAE.0000000000002294CrossRefPubMed

39.

Spaide RF, Ryan EH (2015) Loculation of fluid in the posterior choroid in eyes with central serous Chorioretinopathy. Am J Ophthalmol 160:1211–1216. https://doi.org/10.1016/j.ajo.2015.08.018CrossRefPubMed

40.

Battista M, Borrelli E, Veronese C et al (2020) Choroidal rift: a new OCT finding in eyes with central serous Chorioretinopathy. JCM. https://doi.org/10.3390/jcm9072260CrossRefPubMedPubMedCentral

41.

Ahlers C, Geitzenauer W, Stock G et al (2009) Alterations of intraretinal layers in acute central serous chorioretinopathy. Acta Ophthalmol 87:511–516. https://doi.org/10.1111/j.1755-3768.2008.01468.xCrossRefPubMed

42.

Yang J, Wang E, Yuan M, Chen Y (2020) Three-dimensional choroidal vascularity index in acute central serous chorioretinopathy using swept-source optical coherence tomography. Graefes Arch Clin Exp Ophthalmol 258:241–247. https://doi.org/10.1007/s00417-019-04524-7CrossRefPubMed

43.

Baraki H, Feltgen N, Roider J et al (2010) Chorioretinopathia centralis serosa (CCS). Ophthalmologe 107:479–493. https://doi.org/10.1007/s00347-010-2154-3CrossRefPubMed

44.

Bousquet E, Bonnin S, Mrejen S et al (2017) Optical coherence tomography angiography of flat irregular pigment epithelium detachment in chronic central serous Chorioretinopathy. Retina. https://doi.org/10.1097/IAE.0000000000001580CrossRef

45.

Valet V, Lohmann CP, Maier M (2012) Spectral domain OCT in central serous chorioretinopathy: description of retinal changes. Ophthalmologe 109:879–887. https://doi.org/10.1007/s00347-012-2588-xCrossRefPubMed

46.

Matsumoto H, Kishi S, Otani T, Sato T (2008) Elongation of photoreceptor outer segment in central serous chorioretinopathy. Am J Ophthalmol 145:162–168. https://doi.org/10.1016/j.ajo.2007.08.024CrossRefPubMed

47.

Framme C, Walter A, Gabler B et al (2005) Fundus autofluorescence in acute and chronic-recurrent central serous chorioretinopathy. Acta Ophthalmol Scand 83:161–167. https://doi.org/10.1111/j.1600-0420.2005.00442.xCrossRefPubMed

48.

Spaide RF, Klancnik JM (2005) Fundus autofluorescence and central serous chorioretinopathy. Ophthalmology 112:825–833. https://doi.org/10.1016/j.ophtha.2005.01.003CrossRefPubMed

49.

Ayata A, Tatlipinar S, Kar T et al (2009) Near-infrared and short-wavelength autofluorescence imaging in central serous chorioretinopathy. Br J Ophthalmol 93:79–82. https://doi.org/10.1136/bjo.2008.141564CrossRefPubMed

50.

von Rückmann A, Schmidt KG, Fitzke FW et al (1999) Serous central chorioretinopathy. Acute autofluorescence of the pigment epithelium of the eye. Ophthalmologe 96:6–10. https://doi.org/10.1007/s003470050367CrossRef

51.

von Rückmann A, Fitzke FW, Fan J et al (2002) Abnormalities of fundus autofluorescence in central serous retinopathy. Am J Ophthalmol 133:780–786. https://doi.org/10.1016/s0002-9394(02)01428-9CrossRef

52.

Bujarborua D, Nagpal PN, Deka M (2010) Smokestack leak in central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 248:339–351. https://doi.org/10.1007/s00417-009-1212-5CrossRefPubMed

53.

Gajdzik-Gajdecka U, Dorecka M, Nita E et al (2012) Indocyanine green angiography in chronic central serous chorioretinopathy. Med Sci Monit 18:CR51–CR57. https://doi.org/10.12659/msm.882455CrossRefPubMedPubMedCentral

54.

Guyer DR (1994) Digital Indocyanine green Videoangiography of central serous Chorioretinopathy. Arch Ophthalmol 112:1057. https://doi.org/10.1001/archopht.1994.01090200063023CrossRefPubMed

55.

Bonini Filho MA, de Carlo TE, Ferrara D et al (2015) Association of choroidal neovascularization and central serous Chorioretinopathy with optical coherence tomography angiography. JAMA Ophthalmol 133:899. https://doi.org/10.1001/jamaophthalmol.2015.1320CrossRefPubMed

56.

de Carlo TE, Bonini Filho MA, Chin AT et al (2015) Spectral-domain optical coherence tomography angiography of choroidal neovascularization. Ophthalmology 122:1228–1238. https://doi.org/10.1016/j.ophtha.2015.01.029CrossRefPubMed

57.

van Rijssen TJ, van Dijk EHC, Yzer S et al (2019) Central serous chorioretinopathy: towards an evidence-based treatment guideline. Prog Retin Eye Res 73:100770. https://doi.org/10.1016/j.preteyeres.2019.07.003CrossRefPubMed

58.

Yannuzzi LA (2010) Central serous chorioretinopathy: a personal perspective. Am J Ophthalmol 149:361–363. https://doi.org/10.1016/j.ajo.2009.11.017CrossRefPubMed

59.

Venkatesh R, Pereira A, Jayadev C et al (2020) Oral Eplerenone versus observation in the management of acute central serous chorioretinopathy: a prospective, randomized comparative study. Pharmaceuticals 13:170. https://doi.org/10.3390/ph13080170CrossRefPubMedCentral

60.

Lange et al Stellungnahme des Berufsverbandes der Augenärzte Deutschlands, der Deutschen Ophthalmologischen Gesellschaft und der Retinologischen Gesellschaft zur Chorioretinopathia centralis serosa (CCS) Stand 2020. https://www.dog.org/wp-content/uploads/2013/03/Stellungsnahme-Chorioretinopathia-centralis-serosa-CCS-2020_12-1.pdf. Zugegriffen: 1. Febr. 2021

61.

Verma L, Sinha R, Venkatesh P, Tewari H (2004) Comparative evaluation of diode laser versus argon laser photocoagulation in patients with central serous retinopathy: A pilot, randomized controlled trial [ISRCTN84128484. BMC Ophthalmol 4:15. https://doi.org/10.1186/1471-2415-4-15CrossRefPubMedPubMedCentral

62.

Scholz P, Altay L, Fauser S (2017) A review of subthreshold micropulse laser for treatment of macular disorders. Adv Ther 34:1528–1555. https://doi.org/10.1007/s12325-017-0559-yCrossRefPubMedPubMedCentral

63.

Elsner H, Pörksen E, Klatt C et al (2006) Selective retina therapy in patients with central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 244:1638–1645. https://doi.org/10.1007/s00417-006-0368-5CrossRefPubMed

64.

Klatt C, Saeger M, Oppermann T et al (2011) Selective retina therapy for acute central serous chorioretinopathy. Br J Ophthalmol 95:83–88. https://doi.org/10.1136/bjo.2009.178327CrossRefPubMed

65.

Roider J, Brinkmann R, Wirbelauer C et al (2000) Subthreshold (retinal pigment epithelium) photocoagulation in macular diseases: a pilot study. Br J Ophthalmol 84:40–47. https://doi.org/10.1136/bjo.84.1.40CrossRefPubMedPubMedCentral

66.

Wood EH, Karth PA, Sanislo SR et al (2017) Nondamaging retinal laser therapy for treatment of central serous Chorioretinopathy: what is the evidence? Retina 37:1021–1033. https://doi.org/10.1097/IAE.0000000000001386CrossRefPubMed

67.

Chan W‑M, Lam DSC, Lai TYY et al (2003) Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level. Br J Ophthalmol 87:1453–1458CrossRef

68.

Lee JH, Lee SC, Lee CS (2020) Comparison of half-time and half-Irradiance photodynamic therapy in Nonresolving central serous Chorioretinopathy. J Ocular Pharmacol Ther 36:109–115. https://doi.org/10.1089/jop.2019.0003CrossRef

69.

Chan W‑M, Lai TYY, Lai RYK et al (2008) Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial. Ophthalmology 115:1756–1765. https://doi.org/10.1016/j.ophtha.2008.04.014CrossRefPubMed

70.

Cheng C‑K, Chang C‑K, Peng C‑H (2017) Comparison of photodynamic therapy using half-dose of Verteporfin or half-Fluence of laser light for the treatment of chronic central serous Chorioretinopathy. Retina 37:325–333. https://doi.org/10.1097/IAE.0000000000001138CrossRefPubMed

71.

Reibaldi M, Cardascia N, Longo A et al (2010) Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: a nonrandomized clinical trial. Am J Ophthalmol 149:307–315.e2. https://doi.org/10.1016/j.ajo.2009.08.026CrossRefPubMed

72.

Senturk F, Karacorlu M, Ozdemir H et al (2011) Microperimetric changes after photodynamic therapy for central serous chorioretinopathy. Am J Ophthalmol 151:303–309.e1. https://doi.org/10.1016/j.ajo.2010.08.019CrossRefPubMed

73.

Wu ZHY, Lai RYK, Yip YWY et al (2011) Improvement in multifocal electroretinography after half-dose verteporfin photodynamic therapy for central serous chorioretinopathy: a randomized placebo-controlled trial. Retina 31:1378–1386. https://doi.org/10.1097/FTD.0b013e31820beb02CrossRefPubMed

74.

Son BK, Kim K, Kim ES, Yu S‑Y (2019) Long-term outcomes of full-fluence and half-fluence photodynamic therapy for chronic central serous chorioretinopathy. Ophthalmologica 241:105–115. https://doi.org/10.1159/000490773CrossRefPubMed

75.

van Dijk EHC, Fauser S, Breukink MB et al (2018) Half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic central serous Chorioretinopathy. Ophthalmology 125:1547–1555. https://doi.org/10.1016/j.ophtha.2018.04.021CrossRefPubMed

76.

van Rijssen TJ, van Dijk EHC, Scholz P et al (2020) Crossover to photodynamic therapy or micropulse laser after failure of primary treatment of chronic central serous Chorioretinopathy: the REPLACE trial. Am J Ophthalmol 216:80–89. https://doi.org/10.1016/j.ajo.2020.04.007CrossRefPubMed

77.

Shin Y‑I, Kim K‑M, Lee M‑W et al (2020) Long-term results of focal laser photocoagulation and photodynamic therapy for the treatment of central serous chorioretinopathy. Jpn J Ophthalmol 64:28–36. https://doi.org/10.1007/s10384-019-00697-0CrossRefPubMed

78.

Kim DY, Lee JY, Lee EK, Kim JY (2020) Comparison of visual/anatomical outcomes and recurrence rate between oral spironolactone and photodynamic therapy for nonresolving central serous Chorioretinopathy. Retina 40:1191–1199. https://doi.org/10.1097/IAE.0000000000002507CrossRefPubMed

79.

Lee JH, Lee SC, Kim H, Lee CS (2019) Comparison of short-term efficacy between oral spironolactone treatment and photodynamic therapy for the treatment of nonresolving central serous Chorioretinopathy. Retina 39:127–133. https://doi.org/10.1097/IAE.0000000000001913CrossRefPubMed

80.

Artunay O, Yuzbasioglu E, Rasier R et al (2010) Intravitreal bevacizumab in treatment of idiopathic persistent central serous chorioretinopathy: a prospective, controlled clinical study. Curr Eye Res 35:91–98. https://doi.org/10.3109/02713680903428306CrossRefPubMed

81.

Konstantinidis L, Mantel I, Zografos L, Ambresin A (2010) Intravitreal ranibizumab in the treatment of choroidal neovascularization associated with idiopathic central serous Chorioretinopathy. Eur J Ophthalmol 20:955–958. https://doi.org/10.1177/112067211002000524CrossRefPubMed

82.

Nicholson B, Noble J, Forooghian F, Meyerle C (2013) Central serous chorioretinopathy: update on pathophysiology and treatment. Surv Ophthalmol 58:103–126. https://doi.org/10.1016/j.survophthal.2012.07.004CrossRefPubMedPubMedCentral

83.

Cakir B, Agostini H, Lange C (2019) Treatment of central serous chorioretinopathy with mineralocorticoid receptor antagonists. Ophthalmologe 116:189–200. https://doi.org/10.1007/s00347-018-0785-yCrossRefPubMed

84.

Lotery A, Sivaprasad S, O’Connell A et al (2020) Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial. Lancet 395:294–303. https://doi.org/10.1016/S0140-6736(19)32981-2CrossRefPubMed

85.

Schwartz R, Habot-Wilner Z, Martinez MR et al (2017) Eplerenone for chronic central serous chorioretinopathy‑a randomized controlled prospective study. Acta Ophthalmol. https://doi.org/10.1111/aos.13491CrossRefPubMed

86.

Bousquet E, Dhundass M, Lejoyeux R et al (2019) Predictive factors of response to mineralocorticoid receptor antagonists in nonresolving central serous Chorioretinopathy. Am J Ophthalmol 198:80–87. https://doi.org/10.1016/j.ajo.2018.09.034CrossRefPubMed

87.

Fraenkel D, Suffo S, Langenbucher A et al (2020) Eplerenone for treatment of chronic central serous chorioretinopathy. Eur J Ophthalmol. https://doi.org/10.1177/1120672120952648CrossRefPubMed

Titel: Chorioretinopathia centralis serosa
verfasst von: Laurenz Pauleikhoff
Hansjürgen Agostini
Prof. Dr. Clemens Lange
Publikationsdatum: 16.04.2021
Verlag: Springer Medizin
Erschienen in: Die Ophthalmologie / Ausgabe 9/2021
Print ISSN: 2731-720X
Elektronische ISSN: 2731-7218
DOI: https://doi.org/10.1007/s00347-021-01376-7

Neu im Fachgebiet Augenheilkunde

08.04.2024 | Therapieverfahren in der Augenheilkunde | CME

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Chorioretinopathia centralis serosa

Zusammenfassung

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Update Augenheilkunde

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2021

DMEK bei komplizierten Fällen einer bullösen Keratopathie nach multiplen Augenoperationen

Bewerbungsverfahren um ein Clinical Fellowship in den USA unmittelbar nach der Facharztweiterbildung

Diagnostik von Erkrankungen des Sehnervenkopfes in Zeiten von künstlicher Intelligenz und Big Data

Entwicklung von Klassifikationskriterien für Uveitiden von der Standardization of Uveitis Nomenclature (SUN) Working Group

Klinische und echographische Untersuchungsbefunde bei Patienten mit Carotis-Sinus-cavernosus-Fisteln

Telemedizinische Ansätze in der Augenheilkunde in Zeiten von COVID-19

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Update Augenheilkunde